Research Article

Chinese Patent Medicine Liu Wei Di Huang Wan Combined with Antihypertensive Drugs, a New Integrative Medicine Therapy, for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials

Jie Wang,1 Kuiwu Yao,1 Xiaochen Yang,1 Wei Liu,1 Bo Feng,1 Jizheng Ma,2 Xinliang Du,3 Pengqian Wang,4 and Xingjiang Xiong1

1 Department of Cardiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
2 Department of Gastroenterology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
3 Graduate School, China Academy of Chinese Medical Sciences, Beijing 100700, China
4 Department of Endocrinology, Traditional Chinese Medicine Hospital of Mentougou District, Beijing 102300, China

Correspondence should be addressed to Xingjiang Xiong, xadmin@163.com

Received 26 August 2012; Accepted 10 October 2012

Academic Editor: Vassya Bankova

Copyright © 2012 Jie Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. To assess the beneficial and adverse effects of Liu Wei Di Huang Wan (LWDHW), combined with antihypertensive drugs, for essential hypertension. Methods. Five major electronic databases were searched up to August 2012 to retrieve any potential randomized controlled trials designed to evaluate the clinical effectiveness of LWDHW combined with antihypertensive drugs for essential hypertension reported in any language, with main outcome measures as blood pressure. The quality of the included studies was assessed with the Jadad scale and a customized standard quality assessment scale. Results. 6 randomized trials were included. The methodological quality of the trials was evaluated as generally low. The pooled results showed that LWDHW combined with antihypertensive drugs was more effective in blood pressure and the scale for TCM syndrome and symptom differentiation scores compared with antihypertensive drugs alone. Most of the trials did not report adverse events, and the safety is still uncertain. Conclusions. LWDHW combined with antihypertensive drugs appears to be effective in improving blood pressure and symptoms in patients with essential hypertension. However, the evidence remains weak due to the poor methodological quality of the included studies.

1. Introduction

Hypertension is one of the most prevalent and important public health concerns in both developed and developing countries [1–3]. Several studies have demonstrated that successful long-term treatment of hypertension has a significant impact on morbidity and mortality for cardiovascular disease (CVD) and stroke. However, only 53% of patients treated for hypertension had blood pressure actually controlled to ≤140/90 mmHg [4]. Considering these data and the seriousness of the effects of hypertension on the individual and society as a whole, both economically and socially, physicians must look for more effective and alternative ways to achieve the target blood pressure as quickly as possible. Can integrative medicine contribute to combat hypertension more effectively?

Integrative medicine is a relative new discipline which attempts to combine complementary and alternative medicine (CAM) with Western medicine [5]. As Western medicine has been developed based on the scientific method, integrative medicine, therefore, combines the latest modern scientific advances with the most profound perspectives of CAM to regain and preserve health [6]. In China, the integrative medicine mainly refers to the integrated traditional Chinese and Western medicine. Traditional Chinese medicine (TCM), including herbal medicine and acupuncture, is one of the most important parts in CAM. TCM has long been used in the treatment of a wide variety
of illnesses including hypertension [7, 8]. Much of the past literature reflects clinical observations made by physicians in their offices. More recently, with more and more reports of the significance of disease-syndrome combination [9], there are also large numbers of controlled studies based on the use of combination of TCM and Western medicine in the treatment of hypertension [10–14].

Liu Wei Di Huang Wan (LWDHW), a traditional Chinese patent medicine containing six commonly used herbs (Rehmanniae radix, pulp of Cornus, yam, Poria cocos, Alisma orientalis, and Cortex moutan), is widely used to treat hypertension-related signs and symptoms in clinical practice for centuries in China. Recent research showed that LWDHW could lower blood pressure. The mechanism of the prescription maybe related to enriching yin and nourishing kidney in TCM. Biochemically, LWDHW also showed good effect in decreasing the concentrations of ET and vWF in plasma, increasing the content of NO and protecting the function of kidney with essential hypertension [15, 16].

Our previous studies have showed that kidney deficiency syndrome is one of the most important pathogenesis of essential hypertension in TCM, which could be well treated by LWDHW [17]. LWDHW combined with antihypertensive drugs, a new integrative medicine therapy, has been widely used as an alternative and effective method for treating essential hypertension in China currently. A large number of clinical studies reported the clinical effect of LWDHW and LWDHW combined with antihypertensive drugs ranging from case reports and case series to controlled observational studies and randomized clinical trials (RCTs) until now. However, there is no a critically appraised evidence such as systematic reviews or meta-analyses on potential benefit and harm of LWDHW combined with antihypertensive drugs for essential hypertension to justify their clinical use and their recommendation. Understanding the effect of LWDHW combined with antihypertensive drugs for blood pressure, hypertension-related signs and symptoms, quality of life (QOF), and cardiovascular risk factors could be valuable for essential hypertension management. The present paper aims to evaluate the beneficial and harmful effects of LWDHW combined with antihypertensive drugs for treatment of essential hypertension in randomized trials.

2. Methods
2.1. Database and Search Strategies. The literature searches were conducted in Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), Chinese Biomedical Literature Database (CBM), PubMed, and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (August, 2012). All of those searches ended on 10 August, 2012. Ongoing registered clinical trials were searched in the website of Chinese clinical trial registry (http://www.chictr.org/) and international clinical trial registry by the US national institutes of health (http://clinicaltrials.gov/). The following search terms were used individually or combined: “essential hypertension”, “hypertension,” “Liu Wei Di Huang Wan,” “Liu Wei Di Huang Pill,” “clinical trial,” and “randomized controlled trial.” The bibliographies of the included studies were searched for additional references.

2.2. Inclusion Criteria. All the randomized controlled trials (RCTs) of all the prescriptions based on “Liu Wei Di Huang Wan” combined with antihypertensive drugs compared with antihypertensive drugs in patients with hypertension were included. There were no restrictions on population characteristics, language, and publication type. The primary outcome measure was blood pressure (BP), and the secondary outcome measure was the scale for TCM syndrome and symptom differentiation (TCM-SSD) scores. The criteria “significant effective, effective, or not effective” was also included in the outcome measurement. Duplicated publications reporting the same groups of participants were excluded.

2.3. Data Extraction and Quality Assessment. Two authors conducted the literature searching (X. J. Xiong, K. W. Yao), study selection (X. J. Xiong, B. Feng), and data extraction (X. J. Xiong, X. Du) independently. The extracted data included authors, title of study, year of publication, study size, age and sex of the participants, details of methodological information, name and component of Chinese herbs, treatment process, details of the control interventions, outcomes (e.g., blood pressure), and adverse effects for each study. Disagreement was resolved by discussion and reached consensus through a third party (J. Wang). The methodological quality of trials was assessed using the 6 criteria 6 election bias (study design, confounders, blinding, data collection methods, withdrawals, and dropouts) to follow 3 categories: Category A (strong quality): four strong ratings with no weak ratings above. Category B (moderate quality): less than four strong ratings and one weak rating. Category C (weak quality): two or more weak ratings. The quality of included trials were assessed according to the Cochrane Handbook of Systematic Reviews of Interventions (Chapter 8.5) to address the following five criteria: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias.

2.4. Data Synthesis. Revman 5.1 software provided by Cochrane Collaboration was used for data analyses. Dichotomous data were expressed as relative risk (RR) and continuous outcomes as weighted mean difference (WMD), both with 95% confidence intervals (CI). Meta-analysis was performed if the intervention, control, and outcome were the same or similar. The statistical heterogeneity was presented as significant when I square ($I^2$) is over 50% or $P < 0.1$. In the absence of significant heterogeneity, we pooled data using a fixed-effect model ($I^2 < 50\%$), otherwise we used random effects model ($I^2 > 50\%$) [24].

3. Result
3.1. Description of the Included Trials. After primary search of 5 databases, 340 trials were screen out from electronic
Table 1: Characteristics and methodological quality of the included studies.

| Study ID   | Sample | Diagnosis standard                  | Intervention                              | Control                                 | Course (week) | Outcome measure |
|------------|--------|-------------------------------------|------------------------------------------|-----------------------------------------|---------------|-----------------|
| Cai 2004 [18] | 162    | 1999 WHO—ISH GMH                   | LWDHW plus sustained-release nifedipine   | sustained-release nifedipine            | 8             | BP              |
| Zhang 2007 [19] | 68     | Hypertension diagnostic criteria (unclear) | LWDHW plus nifedipine controlled release tablet | Nifedipine controlled release tablet | 4             | BP              |
| Chen et al. 2008 [20] | 97     | CGMH-2005                           | LWDHW plus captopril                      | captopril                               | 8             | BP; adverse effect |
| Zhang et al. 2004 [21] | 78     | 1993 WHO—ISH GMH                   | LWDHW plus enalapril                      | enalapril                               | 7             | BP; TCM-SSD     |
| Zhou et al. 2003 [22] | 100    | 1999 WHO—ISH GMH                   | LWDHW plus nifedipine controlled release tablet | Nifedipine controlled release tablet | 18            | BP; TCM-SSD     |
| Hu et al. 1994 [23] | 50     | Hypertension diagnostic criteria (unclear); TCM diagnostic criteria (unclear) | LWDHW plus nifedipine                  | nifedipine                              | 10            | BP              |

and manual searches as shown in Figure 1, and the majority were excluded due to obvious ineligibility which included irrelevant titles and abstracts (some papers being found from more than one database). After reading the titles and abstracts, a majority of studies were excluded, and only 133 studies were got. 89 trials were excluded because of duplicated publication, 6 trials were excluded due to the animal studies, and the rest 112 trials were noncontrolled clinical trials including case report, case series traditional review. 127 out of the rest of 133 articles were excluded based on the inclusion criteria. In the end, 6 RCTs were reviewed [18–23]. All the trials were conducted in China and published in Chinese. The characteristics of 6 randomized trials were summarized in Table 1.

The 6 RCTs involved 555 patients with essential hypertension. There was a wide variation in the age of subjects (33–78 years). 6 trials specified three diagnostic criteria of hypertension, two trials [18, 22] used 1999 WHO-ISH guidelines for the management of hypertension (1999 WHO-ISH GMH), one trial [20] used Chinese Guidelines for the Management of Hypertension-2005 (CGMH-2005), one trial [21] used 1993 WHO-ISH guidelines for the management of hypertension (1993 WHO-ISH GMH), and two trials [19, 23] only demonstrated patients with essential hypertension. Only one trial [23] demonstrated patients with yin-deficiency and excessive yang syndrome in TCM, and the rest trials have not reported TCM diagnostic criteria yet.

The interventions of all the trials [18–23] included LWDHW combined with antihypertensive drugs as shown in Table 1. The controls included antihypertensive drugs alone. The total treatment duration ranged from 4 weeks to 18 weeks. All of the 6 trials used the blood pressure (BP) as the main outcome measure. Other outcome measures include the scale for TCM syndrome and symptom differentiation (TCM-SSD). Adverse effect was described in details. Three classes were used to evaluate treatment effects, including significant effective, effective, ineffective according to BP and TCM-SSD.

3.2 Methodological Quality of Included Trials. The methodological quality of all the included RCTs was assessed to be of general low according to the predefined quality assessment criteria as shown in Table 2. The randomized allocation of participants, allocation concealment and double-blind were not mentioned in all the six trials. Only one trial [18] has reported drop-out. None of trials had a pre-trial estimation of sample size, which indicated the lack of statistical power to ensure appropriate estimation of the therapeutic effect.
Table 2: Quality assessment of the included randomized controlled trials.

| Included trials       | Sequence generation | Allocation concealment | Blinding of participants personnel and outcome assessors | Incompleteness outcome data | Selective outcome reporting | Other sources of bias | Risk of bias |
|-----------------------|---------------------|------------------------|--------------------------------------------------------|-----------------------------|---------------------------|----------------------|-------------|
| Cai 2004 [18]         | Unclear             | Unclear                | Unclear                                                | Yes                         | No                        | Unclear              | High        |
| Zhang 2007 [19]       | Unclear             | Unclear                | Unclear                                                | Yes                         | No                        | Unclear              | High        |
| Chen et al. 2008 [20] | Unclear             | Unclear                | Unclear                                                | Yes                         | No                        | Unclear              | High        |
| Zhang et al. 2004 [21]| Unclear             | Unclear                | Unclear                                                | Yes                         | No                        | Unclear              | High        |
| Zhou et al. 2003 [22] | Unclear             | Unclear                | Unclear                                                | Yes                         | No                        | Unclear              | High        |
| Hu et al. 1994 [23]   | Unclear             | Unclear                | Unclear                                                | Yes                         | No                        | Unclear              | High        |

Table 3: Analyses of blood pressure.

| Trials                             | Intervention (n/N) | Control (n/N) | RR (95% CI) | P value |
|------------------------------------|--------------------|---------------|-------------|---------|
| LWDHW plus sustained-release nifedipine versus sustained-release nifedipine | 1 90/93           | 52/61         | 5.19 (1.35, 20.04) | 0.02    |
| LWDHW plus captopril versus captopril | 1 45/49           | 43/48         | 1.31 (0.33, 5.20) | 0.70    |
| LWDHW plus enalapril versus enalapril | 1 35/42           | 23/36         | 2.83 (0.98, 8.15) | 0.05    |
| Meta-analysis                      | 3 170/184         | 118/145       | 2.77 (1.37, 5.57) | 0.004   |

All the trials did not mention follow up. We have tried to contact the authors for further detailed information about the article, but regrettably no information could be got till now.

3.3. Effect of the Interventions

3.3.1. Blood Pressure. Three trials [18, 20, 21] used blood pressure decrease to measure the outcome: significant effective (diastolic blood pressure decreased by 10 mmHg reaching the normal range, or diastolic blood pressure has not yet returned to normal, but has been reduced ≥20 mmHg), effective (diastolic blood pressure decreased to less than 10 mmHg reaching the normal range, or diastolic blood pressure decreased by 10–19 mmHg, but did not reach the normal range, or systolic blood pressure decreased ≥30 mmHg), and ineffective (not to meet the above standards). The trial showed significant difference between treatment and control group on the three criteria outcome measurement (RR: 2.77 (1.37, 5.57); P = 0.004). Five trials 19-21, 23-24 compared the effectiveness using the blood pressure value, and significant difference was found between treatment and control group in systolic blood pressure (WMD: −9.31 (−10.75, −7.86); P < 0.00001) and diastolic blood pressure (WMD: −6.27 (−7.69, −4.86); P < 0.00001) (Tables 3, 4, and 5).

3.3.2. TCM-SSD Scores. Two trials [21, 22] used the TCM-SSD scores to measure the outcome: significant effective (The main symptoms such as headache, dizziness, palpitations, insomnia, tinnitus, and irritability disappear, or TCM-SSD scores reduced rate ≥70%), effective (the main symptoms relieved, or 70% > TCM-SSD scores reduced rate ≥30%), and ineffective (the main symptoms do not change, or TCM-SSD scores reduced rate <30%). There is only one trial [21] who reported the TCM-SSD scores decrease. The meta-analysis showed there is significant beneficial effect on the combination group compared to the antihypertensive drugs using alone (RR: 3.04 (1.10, 8.38; P = 0.03) (Table 6). The other trial [22] reported that after 18 weeks of treatment, the scores of main symptoms in hypertension, including headache, insomnia, amnesia, waist soreness, and tinnitus, decreased significantly. As we cannot obtain more details of the TCM-SSD scores, so we cannot get the analysis of comparison between groups (Table 6).

3.3.3. Other Outcomes. One trial [18] showed that after 8 weeks of treatment, the serum level of ET decreased and NO increased in both groups with significant difference in LWDHW plus sustained-release nifedipine group compared to sustained-release nifedipine group. One trial [19] showed that after 4 weeks of treatment, β2-MG reduced significantly in treatment group compared to control group. One trial [20] showed that significant difference was found between treatment and control group in BUN and Cr after 8 weeks of treatment. One trial [22] reported that significant difference was found between treatment and control group in IgG and C3 after 18 weeks of treatment. One trial [23] showed that IgG and C3 decreased in the treatment group.

3.4. Sensitivity Analysis, Subgroup Analysis, and Publication Bias. The number of trials was too small to conduct any sufficient additional analysis of sensitivity, subgroup, and publication bias.

3.5. Adverse Effect. Only one trial mentioned the adverse effect [20]. It mentioned adverse effect such as dry cough during the course. It may be related to the adverse effect of captopril.
The positive effects of LWDHW combined with antihypertensive drugs cannot be drawn from this paper. Large-scale clinical trials with long-term followup were warranted to assess the safety of new integrative medicine therapy properly.

Adverse effect was reported by Chen et al. in 2008 [20] as only dry mouth. The adverse effect was not severe, and it spontaneously recovered without special treatment. The other 5 trials did not report any adverse effects and these were not significantly different between the two treatments. Therefore, due to the limited and inadequate evidence provided by the eligible trials, conclusions about the safety of LWDHW combined with antihypertensive drugs cannot be made from this paper. Large-scale clinical trials with long-term followup were warranted to assess the safety of new integrative medicine therapy properly.

Syndrome is a classification according to subjective symptom and objective sign collected by physician through inspection, auscultation-olfaction, interrogation and palpation [25]. Syndrome differentiation is the basic rule in TCM. Failure to apply syndrome differentiation to clinical trials may result in treatments being ineffective or even harmful, and failure to evaluate the real efficacy of TCM. In this paper, only one trial [23] reported the TCM diagnostic criteria but without further details. The rest five trials [18–22] did not report TCM diagnostic criteria. If syndrome differentiation in TCM was considered into the studies properly, the positive effects could be enhanced.

5. Conclusions

In conclusion, because of the unclear methodological quality of these including trials, a definite conclusion on efficacy and safety associated with Liu Wei Di Huang Wan combined with antihypertensive drugs cannot be drawn from this paper.

| Trials | WMD (95% CI) | P value |
|--------|--------------|---------|
| LWDHW plus sustained-release nifedipine versus sustained-release nifedipine | −10.00 (−11.76, −8.24) | <0.00001 |
| LWDHW plus nifedipine controlled release tablet versus nifedipine controlled release tablet | −10.50 (−24.07, 3.07) | 0.13 |
| LWDHW plus captopril versus captopril | −9.00 (−13.66, −4.34) | 0.002 |
| LWDHW plus nifedipine controlled release tablet versus nifedipine controlled release tablet | −8.00 (−11.35, −4.65) | <0.00001 |
| LWDHW plus nifedipine versus nifedipine | −3.00 (−10.91, 4.91) | 0.46 |
| Meta-analysis | −9.31 (−10.75, −7.86) | <0.00001 |

### Table 5: Analyses of diastolic blood pressure.

| Trials | WMD (95% CI) | P value |
|--------|--------------|---------|
| LWDHW plus sustained-release nifedipine versus sustained-release nifedipine | −7.00 (−8.74, −5.26) | <0.00001 |
| LWDHW plus nifedipine controlled release tablet versus nifedipine controlled release tablet | −2.25 (−11.90, 7.40) | 0.65 |
| LWDHW plus captopril versus captopril | −6.75 (−11.26, −2.24) | 0.003 |
| LWDHW plus nifedipine controlled release tablet nifedipine controlled release tablet | −4.00 (−7.23, −0.77) | 0.02 |
| LWDHW plus nifedipine versus nifedipine | −6.00 (−14.46, 2.46) | 0.16 |
| Meta-analysis | −6.27 (−7.69, −4.86) | <0.00001 |

4. Discussion

This paper included 6 randomized trials and a total of 555 participants. Liu Wei Di Huang Wan combined with antihypertensive drugs, a new integrative medicine therapy, showed significant benefit on decreasing blood pressure and improving symptoms and signs as compared with conventional treatment for essential hypertension. However, due to the low-quality methodology and potential publication bias, a definite conclusion of the beneficial effectiveness of LWDHW combined with antihypertensive drugs in treating essential hypertension could not be drawn. The positive findings should be interpreted conservatively due to the following facts.

All the six trials included had improper study design or method used, such as lack of randomization or allocation concealment. No trials reported randomization procedure clearly and only mentioned that “patients were randomized into two groups”. So, it is hard to judge whether randomization was conducted properly and really. All the trials haven’t mentioned allocation concealment and double-blind. Therefore, it is possible that some of the trials are not true RCTs. And two trials including Cai 2004 and Zhang 2007 [18, 19], only have one author. It is impossible for an RCT to be done properly in terms of randomization and allocation concealment by one doctor totally. Publication bias could also be a factor. We have tried to take all measures to contact authors to get further information either by telephone or email. Unfortunately, no replies and informations was got. Subsequently, no clear conclusion could be made from these trials.
Before recommending Liu Wei Di Huang Wan combined with antihypertensive drugs as an alternative treatment measure in hypertensive patients, more rigorous trials with high quality are needed to give high level of evidence.

**Author’s Contribution**

J. Wang, K. Yao, X. Yang, B. Feng, X. Du, and P. Wang contributed equally to this paper. All the authors contributed to the writing of this paper.

**Conflicts of Interests**

The authors declare that they have no conflict of interests.

**Acknowledgments**

The current work was partially supported by the National Basic Research Program of China (973 Program, no. 2003CB517103) and the National Natural Science Foundation Project of China (no. 90209011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

**References**

[1] K. Sliwa, S. Stewart, and B. J. Gersh, “Hypertension: a global perspective,” *Circulation*, vol. 123, no. 24, pp. 2892–2896, 2011.

[2] E. G. Nabel, “Cardiovascular disease,” *New England Journal of Medicine*, vol. 349, no. 1, pp. 60–72, 2003.

[3] A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” *Hypertension*, vol. 42, no. 6, pp. 1206–1252, 2003.

[4] D. Levy, M. G. Larson, R. S. Vasan, W. B. Kannel, and K. K. L. Ho, “The progression from hypertension to congestive heart failure,” *Journal of the American Medical Association*, vol. 275, no. 20, pp. 1557–1562, 1996.

[5] C. Chang and M. E. Gershwin, “Integrative medicine in allergy and immunology,” *Clinical Reviews in Allergy and Immunology*. In press.

[6] D. Su and L. Li, “Trends in the use of complementary and alternative medicine in the United States: 2002–2007,” *Journal of Health Care for the Poor and Underserved*, vol. 22, no. 1, pp. 296–310, 2011.

[7] M. Jiang, C. Zhang, H. Cao, K. Chan, and A. Lu, “The role of Chinese medicine in the treatment of chronic diseases in China,” *Planta Medica*, vol. 77, no. 9, pp. 873–881, 2011.

[8] H. Xu and K. Chen, “Integrative medicine: the experience from China,” *Journal of Alternative and Complementary Medicine*, vol. 14, no. 1, pp. 3–7, 2008.

[9] J. Wang and X. J. Xiong, “Current situation and perspectives of clinical study in integrative medicine in China,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 268542, 11 pages, 2012.

[10] G. W. Zhong, M. J. Chen, Y. H. Luo et al., “Effect of Chinese herbal medicine for calming Gan and suppressing hyperactive yang on arterial elasticity function and circadian rhythm of blood pressure in patients with essential hypertension,” *Chinese Journal of Integrative Medicine*, vol. 17, no. 6, pp. 414–420, 2011.

[11] F. A. Flachskampf, J. Gallasch, O. Gefeller et al., “Randomized trial of acupuncture to lower blood pressure,” *Circulation*, vol. 115, no. 24, pp. 3121–3129, 2007.

[12] H. Li, L. T. Liu, W. M. Zhao et al., “Effect of traditional and integrative regimens on quality of life and early renal impairment in elderly patients with isolated systolic hypertension,” *Chinese Journal of Integrative Medicine*, vol. 16, no. 3, pp. 216–221, 2010.

[13] L. Lu, J. Z. Zhou, L. Wang, and T. X. Zhang, “Effects of Xuezhihakang and Pravastatin on circulating endothelial progenitor cells in patients with essential hypertension,” *Chinese Journal of Integrative Medicine*, vol. 15, no. 4, pp. 266–271, 2009.

[14] E. A. Macklin, P. M. Wayne, L. A. Kalish et al., “Stop Hypertension with the Acupuncture Research Program (SHARP): results of a randomized, controlled clinical trial,” *Hypertension*, vol. 48, no. 5, pp. 838–845, 2006.

[15] T. D. Zhang and C. X. Li, “Protective effects of liuwei dihuang wan on the kidney of patients with senile hypertension,” *Shi Jie Ke Xue Ji Shu: Zhong Yi Yao Xian Dai Hua*, vol. 8, no. 2, pp. 102–104, 2006.

[16] S. X. Wu and X. S. Lin, “Clinical effect of liuwei dihuang wan on the level of vWF in patients with hypertension,” *Fujian Zhong Yi Yao*, vol. 31, no. 6, pp. 5–6, 2000.

[17] J. Wang and X. J. Xiong, “Control strategy on hypertension in Chinese medicine,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 284847, 6 pages, 2012.

[18] L. H. Cai, “Clinical effect of Liu Wei Di Huang Wan on ET and NO in patients with senile hypertension,” *Zhong Yi Yao Xue Kan*, vol. 22, no. 7, pp. 1280–1281, 2004.

[19] Y. B. Zhang, “Clinical effect of Liu Wei Di Huang Wan on β2-MG in patients with essential hypertension,” *Gansu Zhong Yi*, vol. 20, no. 9, pp. 54–55, 2007.

[20] G. Q. Chen, W. Y. Lai, K. Chen, and X. J. Xu, “Clinical study on the therapy of elder essential hypertension using liu wei di huang pill and captopril,” *Hannan Yi Xue Yuan Xue Bao*, vol. 14, no. 4, pp. 357–358, 2008.

[21] N. Zhang, L. Liu, and J. Jin, “Clinical study on essential hypertension treated by the therapy of combination of traditional Chinese medicine and western medicine,” *Zhong Yi Yao Xin Xi*, vol. 21, no. 3, pp. 29–30, 2004.

[22] Y. L. Zhou, Z. W. Zhou, and M. X. Tang, “Clinical study of combination of liu wei di huang pills and basintom for the treatment of essential hypertension,” *Hunan Zhong Yi Yao Dao Bao*, vol. 9, no. 11, pp. 15–16, 2003.
[23] L. B. Hu, H. Y. Ma, Z. F. Yang, and M. F. Ren, “Clinical immunology of essential hypertension belonged to the types of Yang hyperactivity and Yin deficiency treated by combining Luiwei Rehmannia pill with nifedipine,” Xinxiang Yi Xue Yuan Xue Bao, vol. 11, no. 1, pp. 279–282, 1994.

[24] J. P. T. Higgins and S. Green, Corchrane Reviewers’ Handbook 5. 1. 0, Review Manager, 2011.

[25] J. Wang, P. Q. Wang, and X. J. Xiong, “Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine,” Internal Medicine, vol. 2, no. 3, article 113, 2012.
